30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q13 Revenue: Integra LifeSciences

  • Orthopaedic sales $76.5MM, -5%
  • U.S. Extremities $33.5MM, +5%
  • U.S. Spine & Other $42.9MM, -12%


  • Orthobiologics flat due to backorders in collagen and ceramic bone void fillers; supply should return to normal by end of 3Q
  • Attributed Spine & Other decline to market softness, price pressure and execution challenges (e.g., converting ineffective distributors out/bringing in new ones); 60% of decline was private label, 40% spine
  • In 3Q, received 510(k) clearance for Titan Reverse Shoulder; limited U.S. launch occurring in 3Q with full global launch expected in 1Q14